Successful Management of Complex Pediatric and Neonatal Wounds With Methylene Blue and Gentian Violet Foam Dressings

Vita Boyar, MD

Wounds. 2021;33(10):253-259.

Limitations

The main limitation of this study is that it was a retrospective, single-center case series with a limited number of patients. Outcomes reported reflect the author's experiences.

1 2 3 4 5 6

Next Section

Wounds. 2021;33(10):253-259. © 2021 HMP Communications, LLC

Table. Patient Demographics
CASE No.	AGE	ETIOLOGY	PREVIOUS TREATMENT(S)	ADDITIONAL PRODUCTS AT TIME OF MB/GV APPLICATION	ADDITIONAL PRODUCTS AFTER MB/GV APPLICATION	DESIRED OUTCOME(S)	MB/GVRELATED, YES/NO
1	55 days, 33-week GA	Giant omphalocele skin breakdown	Polymer skin protectant, silver foam	Outer dressing	None	Complete epithelialization	Yes
2	76 days, 36-week GA	Giant omphalocele skin breakdown	None	Outer dressing	None	Complete epithelialization	Yes
3	10 days, 33-week GA	PIVE	None	Enzymatic debrider, outer dressing	Hydrolyzed collagen powder	Debrided wound bed, followed by complete epithelialization with additional products	Yes
4	20 days, 29-week GA	PIVE	None	Outer dressing	Medical-grade honey	Complete wound preparation, epithelialization with additional products	Yes
5	8 days, FT	Dehisced surgical abdominal wound	Hydrofiber	None	None	Granulation tissue, decreased wound size prior to transfer	Yes
6	2 months	Peristomal irritant dermatitis	Polymer skin protectant, zinc-based products, crusting	None	None	Resolution of dermatitis	Yes
7	14 years	Sacral pressure injury	Enzymatic debrider	Outer dressing	NA	Clean wound bed, granulation tissue	Yes
8	15 years	Sacral pressure injury	Silver-based hydrofiber	Enzymatic debrider	Hydrolyzed collagen powder, amniotic membrane-based dressing	Clean wound bed, granulation tissue, decrease in size	Yes

MB/GV: methylene blue/gentian violet; GA: gestational age; PIVE: peripheral intravenous catheter extravasation; FT: full term; NA: not available

processing....

What to Read Next on Medscape

Special Coverage: COVID-19